- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05237804
Ocena interwencji w celu skrócenia czasu leczenia pacjentów z TAVI (TREAT)
Evaluation d'Une Intervention Pour Reduire le Delai de Traitement Des Pacjenci Traites Par TAVI
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).
Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.
In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Brest, Francja
- Brest University Hospital
-
Rouen, Francja
- CHU de Rouen
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patient over 18 years of age;
- Aortic stenosis
- Indication of TAVI
- Patient affiliated or benefiting from a health insurance scheme
- Patient having read and understood the information letter and having signed the consent form
Exclusion Criteria:
- TAVI indication not retained
- Patient who are not fluent in French and have no one around them to translate,
- Patient who do not have access to the Internet (at home or in their immediate environment)
- Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
- Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Brak interwencji: Control group
The randomized centres in this group will not change their practices. |
|
|
Eksperymentalny: Patient component
The randomized centres in this group will be required to present patients with:
|
Video, booklet, website |
|
Eksperymentalny: Organisational component
The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times. |
Coronarography, CT-scan, anesthesia... |
|
Eksperymentalny: Patient and organisational components
The randomized centres in this group will have to implement the two components. |
Video, booklet, website Coronarography, CT-scan, anesthesia... |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Ramy czasowe: Month 6
|
Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months |
Month 6
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Time to care, in days
Ramy czasowe: Month 6
|
The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure |
Month 6
|
|
Mortality rate
Ramy czasowe: Months 3 and 6
|
The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure |
Months 3 and 6
|
|
Patients' health-related quality of life
Ramy czasowe: Baseline, Months 3 and 6
|
Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L). |
Baseline, Months 3 and 6
|
|
Patient knowledge of the disease and the TAVI procedure
Ramy czasowe: Baseline, Month 3
|
Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score). |
Baseline, Month 3
|
|
Medication compliance
Ramy czasowe: Month 6
|
Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance). |
Month 6
|
|
Patient satisfaction
Ramy czasowe: Month 6
|
Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale |
Month 6
|
|
Number of visits to the patient section of the website
Ramy czasowe: Month 6
|
The number of visits to the website will be assessed through Googleanalytics® |
Month 6
|
|
Number of visits to the professional section of the website
Ramy czasowe: Month 6
|
The number of visits to the website will be assessed through Googleanalytics® |
Month 6
|
|
Acceptability of the intervention for participating centers
Ramy czasowe: Month 6
|
The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment. |
Month 6
|
|
Intervention components' dose and fidelity
Ramy czasowe: Month 6
|
Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol. |
Month 6
|
|
Reached populations
Ramy czasowe: Month 6
|
Percentage of target individuals who benefit from activities of each component of the intervention |
Month 6
|
|
Intervention components' adaptation
Ramy czasowe: Month 6
|
Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided. |
Month 6
|
|
Incremental cost-effectiveness ratio
Ramy czasowe: Month 6
|
The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire |
Month 6
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Helene Eltchaninoff, Pr, University Hospital, Rouen
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2021/0226/HP
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .